News

But rising Chinese import tariffs due to the trade war with the U.S. and longer-term concerns about costs or access are ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...
Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...
If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive.
Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...
Merck & Co., Inc. recently reported robust earnings, yet the market response was lukewarm. Investors overlooked several positive aspects beneath the surface. Unusual expenses, totaling US$4.2 billion, ...
MSD, known as Merck & Co Inc in the United States and Canada, has been in Singapore for 30 years, employs over 1,800 people, ...
Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...
The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...